Latest news

New film from Eiffage about Ironhand®

Bioservo has finished a successful long term trial with Toyota Motor North America

World’s first soft robotic muscle strengthening system. Developed in collaboration with leading Fortune 500 companies

Menu

18 Oct, 2019  ·  Regulatory information

The rights issue is registered and the trading in Paid Subscription Shares ceases

Bioservo Technologies AB (publ) ("Bioservo" or the “Company") has completed a rights issue of shares that closed on September 30, 2019. The rights issue is now registered with the Swedish Companies Registration Office and the last day for trading in paid subscribed shares ("BTA") will be Tuesday, October 22, 2019. The record date will be Thursday, October 24, 2019, after which the BTAs are converted into ordinary shares on Monday, October 28, 2019.

For further information please contact:

Petter Bäckgren

VD

petter.backgren@bioservo.com

+46 8 21 17 10

or

Jacob Michlewicz

CFO

jacob.michlewicz@bioservo.com

+46 8 21 17 10

About Bioservo Technologies
Bioservo Technologies AB (publ) is a technology and development company that combines medical science with modern robotics. The company holds a leading global position within soft exoskeleton technology – wearable non-invasive devices – for people in need of extra power to optimize the body’s endurance and performance, or for people with reduced muscle strength.

Bioservo Technologies was founded in 2006 in collaboration between researchers at the Royal Institute of Technology and a doctor at Karolinska Hospital. Bioservo Technologies is a Swedish public limited company with headquarters in Stockholm.

FNCA Sweden AB, +46(0)8 528 00399, info@fnca.se is the Company’s Certified Adviser on Nasdaq First North Growth Market.

For more information, please visit www.bioservo.com